Publication

Progestins used for hormonal contraception in Switzerland: study of their effects on the breast epithelium

Publications associées (30)

Characterization of the gut-bone marrow axis through bile acid signaling

Communication between the intestine and other organs such as the lungs, brain or bones is mediated by several metabolites, like short-chain fatty acids or bile acids, that relay information about nutritional and microbiota status. Bile acids are endogenous ...

EPFL2024

Multiomic analysis of HER2-enriched and AR-positive breast carcinoma with apocrine differentiation and an oligometastatic course: a case report

Andrea Cavalli

Breast carcinoma is the most prevalent cancer among women globally. It has variable clinical courses depending on the stage and clinical-biological features. This case report describes a 56-year-old female with invasive breast cancer without estrogen or pr ...

FRONTIERS MEDIA SA2023

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma

Cathrin Brisken, Laura Battista, Georgios Sflomos

Simple Summary Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and is often detected at an advanced stage. Up to 30% of ILC cases relapse and present a challenge for treatment. Unfortunately, there are few mod ...

MDPI2023

Metabolic dependencies of metastasis-initiating cells in female breast cancer

Jörg Hülsken, Albert Santamaria Martinez, Pierre Vincent Dessen, Laurent Nam Ky Beziaud, Candice Megan T Young, Angela Madurga Alonso

Understanding the mechanisms that enable cancer cells to metastasize is essential in preventing cancer progression. Here we examine the metabolic adaptations of metastasis-initiating cells (MICs) in female breast cancer and how those shape their metastatic ...

Nature Portfolio2023

Metabolic dependencies of metastasis-initiating cells in breast cancer

Candice Megan T Young

Metastasis is the process by which cancer cells from the primary tumor travel through the blood stream to generate a secondary tumor site in a distant organ. Although very few cells are able to make this journey, the resulting effects are dire since most c ...

EPFL2023

Cancer hallmarks intersect with neuroscience in the tumor microenvironment

Douglas Hanahan

The mechanisms underlying the multistep process of tumorigenesis can be distilled into a logical framework involving the acquisition of functional capabilities, the so-called hallmarks of cancer, which are collectively envisaged to be necessary for maligna ...

CELL PRESS2023

Development of a novel Chimeric Antigen Receptor (CAR) for its use in Natural Killer (NK) cells for cancer treatment and beyond

Angela Madurga Alonso

The use of CAR technologies has revolutionized cancer treatment. Their unprecedented efficacy against B cell malignancies has opened the doors for a lot of excitement and research in the field. These synthetic receptors are composed of an antigen recogniti ...

EPFL2023

The Antioxidant and Proapoptotic Effects of Sternbergia clusiana Bulb Ethanolic Extract on Triple-Negative and Estrogen-Dependent Breast Cancer Cells In Vitro

Laure Menin, Natalia Gasilova, Maria Younes

Background: Sternbergia clusiana belongs to the Amaryllidaceae family and is recognized for the valuable biological activity of its major bioactive compounds. The aim of the current is to evaluate the anticancer effects of the ethanolic bulb extract of Ste ...

MDPI2023

Medical and Personal Characteristics Can Predict the Risk of Lung Metastasis

Michele De Palma, Nahal Mansouri

Aims: Understanding the correlations between underlying medical and personal characteristics of a patient with cancer and the risk of lung metastasis may improve clinical management and outcomes. We used machine learning methodologies to predict the risk o ...

2023

Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

Cathrin Brisken, Carlos Henrique Venturi Ronchi

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the prog-esterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized ...

AMER ASSOC CANCER RESEARCH2023